Resected Melanoma Stage III or Stage IV research hub

A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

This study is looking at a new medicine called ABP 206 to see if it works as similarly as an existing medicine, Opdivo (nivolumab). It's for people who have had some types of skin cancer (melanoma) removed. The aim is to see if ABP 206 can be just as good.